GALAPAGOS NV/S (GLPG) Stock Rating Lowered by BidaskClub

Share on StockTwits

GALAPAGOS NV/S (NASDAQ:GLPG) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday, January 25th.

GLPG has been the subject of several other research reports. Zacks Investment Research downgraded shares of GALAPAGOS NV/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 4th. ValuEngine raised shares of GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 10th. Morgan Stanley upped their target price on shares of GALAPAGOS NV/S from $127.00 to $131.00 and gave the company an “overweight” rating in a research note on Monday, November 5th. Cantor Fitzgerald assumed coverage on shares of GALAPAGOS NV/S in a research note on Wednesday, December 19th. They issued an “overweight” rating and a $130.00 target price for the company. Finally, Credit Suisse Group upgraded shares of GALAPAGOS NV/S from a “neutral” rating to an “outperform” rating in a report on Thursday, December 13th. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $122.00.

Shares of GLPG traded up $0.23 on Friday, reaching $101.53. 56,561 shares of the company’s stock were exchanged, compared to its average volume of 78,690. The company has a market cap of $5.20 billion, a price-to-earnings ratio of -38.46 and a beta of 1.70. GALAPAGOS NV/S has a 12 month low of $85.00 and a 12 month high of $122.28.

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. acquired a new position in GALAPAGOS NV/S during the third quarter worth $399,000. Marshall Wace LLP bought a new stake in GALAPAGOS NV/S during the third quarter worth $15,319,000. Bank of America Corp DE raised its position in GALAPAGOS NV/S by 11.7% during the second quarter. Bank of America Corp DE now owns 9,758 shares of the biotechnology company’s stock worth $899,000 after acquiring an additional 1,025 shares in the last quarter. Credit Suisse AG raised its position in GALAPAGOS NV/S by 52.0% during the third quarter. Credit Suisse AG now owns 190,376 shares of the biotechnology company’s stock worth $21,404,000 after acquiring an additional 65,094 shares in the last quarter. Finally, Marshall Wace North America L.P. raised its position in GALAPAGOS NV/S by 258.1% during the third quarter. Marshall Wace North America L.P. now owns 23,994 shares of the biotechnology company’s stock worth $2,697,000 after acquiring an additional 17,294 shares in the last quarter. Institutional investors and hedge funds own 18.08% of the company’s stock.

About GALAPAGOS NV/S

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Read More: Reverse Stock Split

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply